It is widely held that elevated intracardiac pressures can provoke ventricular arrhythmias. In isolated hearts and in vivo animals and man, acute ventricular dilatation has potentially arrhythmogenic effects. However, although elevated intraventricular pressure can elicit ventricular arrhythmias in isolated hearts and animal models, there is limited evidence supporting a comparable effect in humans.

Although ejection fraction, functional class, and N-terminal probrain natriuretic peptide have been shown to be independent predictors of VT/VF occurrence in patients with an implantable cardioverter-defibrillator (ICD), the influence of volume status and intracardiac hemodynamics on ventricular arrhythmia susceptibility has not been examined in man. Implanted devices, designed to provide long-term hemodynamic measures, offer an opportunity to evaluate directly the relation between intracardiac pressures and ventricular arrhythmia frequency.

The purpose of this study was to assess the relationship between intracardiac hemodynamic pressures and the development of clinical ventricular arrhythmias in the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients with Chronic Heart Failure (REDUCEhf) trial. We specifically attempted to document whether an increase of intracardiac filling pressure in patients with a history of heart failure (HF) was a determinant of increased risk of spontaneous VT/VF.

Background—The implantation of a combination hemodynamic monitor-cardioverter-defibrillator in the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients with Chronic Heart Failure (REDUCEhf) study allowed assessment of the relationship between daily intracardiac pressure and occurrence of ventricular arrhythmic (VT/VF) events.

Methods and Results—Median estimated pulmonary artery diastolic pressures (ePAD) were calculated every 24 hours in 378 subjects with New York Heart Association functional class II-III heart failure who had at least 60 days of hemodynamic data. Forty-six subjects experienced 140 VT/VF events on 80 unique study days in which daily median ePAD was available. The incidence of days with VT/VF events was significantly higher when the daily median ePAD for a subject was elevated, defined as >1 SD above that subject’s average median ePAD for the whole study: (2.8 episode days per patient-year compared with 1.7 episode days per patient-year; P=0.040). However, the incidence of days with VT/VF events was not significantly different on days when ePAD was >25 mm Hg compared with days when ePAD was <25 mm Hg. For all 378 subjects, the risk of VT/VF increased with average median ePAD calculated over the whole follow-up period (odds ratio, 1.072 for a 1-mm Hg increase; 95% confidence interval, 1.023–1.124; P=0.003).

Conclusions—There is significant positive association between average daily median ePAD and risk for VT/VF. Among patients with VT/VF, elevated intracardiac pressures are associated with higher VT/VF risk only when the definition of increased pressure is subject specific. (Circ Arrhythm Electrophysiol. 2013;6:272-278.)

Key Words: devices for heart failure ◼ electrophysiology ◼ heart failure ◼ hemodynamics ◼ ventricular arrhythmia
patients with New York Heart Association (NYHA) functional class II and III HF receiving stable and maximally tolerated medical therapy. Subjects were required to have a HF hospitalization in the 12 months before enrollment and an indication for ICD therapy but no indication for cardiac resynchronization therapy.

**Hemodynamic Monitoring**

Patients were implanted with an ICM-ICD device attached to both a single-standard transvenous ICD lead and a second transvenous hemodynamic pressure-sensing lead positioned in the right ventricular outflow tract. The ICM continuously measured and stored right ventricular dP/dt, systolic and diastolic pressures, and an estimate of pulmonary artery diastolic pressure (ePAD). Pulmonary artery diastolic pressure was estimated as the pressure in the right ventricle at the time of maximum dP/dt (the time of pulmonary valve opening). All pressures were corrected for ambient atmospheric pressure. ePAD measurements every 8 seconds were used to calculate a median ePAD for an 8-minute period. These were then used to calculate a daily median ePAD for each 24-hour period. Daily median pressures were stored on an Internet information system available for analysis.

In the treatment group, hemodynamic information was used for HF management. Management goals were to maintain a "euvolemic" state, determined individually for each subject by managing physicians, with a recommendation to more aggressively treat increases in ePAD than decreases and, in at least a subgroup, to adjust therapy specifically when daily median ePAD was >1 SD above or >2 SD below the subject-specific baseline pressure. We considered this definition of hypervolemia and hypovolemia in our initial analysis. In the control group, hemodynamic information was stored but was not available to the managing physician. For the purposes of the present analysis, data from both groups were relevant and used. Patients were randomized follow-up for 12 months. Although the trial was designed to enroll 1300 patients, enrollment was prematurely stopped after 400 implants because of IHM sensor lead failures.

**Device Settings and Arrhythmia Detection**

ICD detection programming was left to individual investigators with the following recommended settings: VF zone (On) <320 ms, detection 18 of 24 intervals; VT zone (On or Monitor) <360 ms or VT CL + 40 ms, detection 16 beats; wavelet matching On; Egm=scan-RV coil. The ICM stored the intervals of detected tachycardias along with electrograms and a QRS snapshot. The device was capable of capturing up to 150 episodes of VT/VF and 50 supraventricular or nonsustained tachycardias for download. Pressure data were not used for VT/VF discrimination.

Spontaneous, stored ventricular episodes defined by therapy delivery (ICD shock in 48, ATP in 71, both in 26) and duration >30 seconds (mean duration, 20 seconds; range, 6–468 seconds) were reviewed and classified initially by the investigators. All episodes were also classified by field clinical engineers for the trial. Episodes were submitted for adjudication by electrophysiologists on the Adverse Events Adjudication Committee if the first 2 classifications were inconsistent. In addition, a subset of episodes was reexamined by 2 of the authors (M.R., D.B.); a consistency of >95% was observed. All episodes were available to the managing physician. For the purposes of the present analysis, data from both groups were relevant and used. Patients were in randomized follow-up for 12 months. Although the trial was designed to enroll 1300 patients, enrollment was prematurely stopped after 400 implants because of IHM sensor lead failures.

**Statistical Analysis**

**Comparison of Patients With and Without VT/VF Events**

Subjects with at least 60 days of ePAD data available were included in the analysis. Differences in baseline demographics were compared with a 2-sample t test (continuous variables) or with a Fisher exact test (categorical variables). Data are presented as mean ± SD or as percentages unless otherwise noted.

**Average Follow-up ePAD as a Predictor of VT/VF Events**

For each subject, the average follow-up median ePAD during the 12-month randomized period was computed from daily median ePAD data. A univariate logistic regression model was used to investigate the relationship between average follow-up median ePAD and the risk of having at least 1 VT/VF episode during the 12-month follow-up period. Propensity score methods were used to evaluate the association between average follow-up median ePAD and the risk of having VT/VF after adjusting for potential confounding factors in a multivariable logistic model. Propensity scores for each subject were constructed from the variables: years since HF diagnosis, baseline 6-minute hall walk distance, Medical Outcome Study Short Form 12 Health Survey (SF-12) physical health assessment score, baseline left ventricular ejection fraction, baseline blood urea nitrogen, age, sex, treatment group, NYHA functional class III, history of ventricular arrhythmia, history of atrial fibrillation, and chronic obstructive pulmonary disease. Each patient's propensity score represents the risk for VT/VF based on this set of variables. The propensity score for each subject was then included in the logistic regression model to adjust for these characteristics.

**Relationship of Daily ePAD to VT/VF Risk**

Because the daily median ePAD is calculated as the median of ePADs calculated every 8 minutes during each 24-hour period, it is unlikely to be influenced by episodes of VT/VF successfully treated by the ICD typically lasting <1 minute (96% of episodes). This conclusion is supported by the observation that the daily median ePAD on the day after a VT/VF episode was not significantly different than the daily median ePAD on the day of the VT/VF episode (mean difference, ±3.7 mm Hg; P=0.914).

However, occasional VT/VF episodes transiently increased ePAD, which quickly normalized (and therefore did not increase daily median ePAD). A representative example is shown in Figure 1. To avoid the influence of VT/VF episodes that occurred on the same day subsequent to a transient increase in ePAD after an initial VT/VF episode, our primary analysis considered only the first VT/ VF event on any single day by analyzing the number of days with at least 1 VT/VF event.

To test the hypothesis that patients are more likely to experience a VT/VF event during a period of abnormal pressure, we examined the annualized rate of days with VT/VF during periods of elevated, low, and normal intracardiac pressures only among subjects who experienced at least 1 adjudicated VT/VF event. For each subject with at least 1 episode of adjudicated VT/VF who had at least 60 days of hemodynamic data available, the subjects' mean and SD of their daily median ePAD values were computed from days the subjects were free from VT/VF. Then, for each subject, on every day ePAD data were available; the subject was classified as being hypervolemic, euvolemic, or hypovolemic based on whether the intracardiac pressure for that day was elevated, normal, or low, respectively. Pressure state was determined in a patient-specific manner: if the daily median ePAD was >1 SD higher than the subject’s average daily median ePAD across the whole study period, then the subject was categorized as hypervolemic for that day; if the daily median ePAD was >2 SDs lower than the subject’s average daily median ePAD, then the subject was considered hypovolemic for that period. Otherwise, the subject was considered euvolemic.

Within each subject and pressure state, the number of days the subject spent in each pressure state, number of days with a VT/VF episode, and number of VT/VF episodes were determined. The ePAD on the day of VT/VF was used to calculate volume status associated with VT/VF. The number of days with at least 1 episode of VT/VF was used to calculate the annualized rate of VT/VF days for all subjects within each pressure state. The number of VT/VF episodes was used to calculate the annualized rate of VT/VF for all subjects within each pressure state. Repeated measures Poisson models were used to compare the annualized rate of days with VT/VF, and annualized rate of VT/VF between pressure states with P values <0.05 was considered significant. In subsequent analyses, hypervolemia, hypovolemia, and euvolemia were defined in an absolute manner, based on daily ePAD in mm Hg.
Results

Baseline Characteristics
Of the 400 patients randomized in the REDUCEhf study, 399 patients were successfully implanted with an IHM-ICD device. The 378 subjects with at least 60 days of ePAD data (mean of 334±74 days with ePAD available) during the 12-month randomized follow-up period were included in the present analysis. There was no difference between the treatment group (194 subjects) and control group (184 subjects) in the risk of VT/VF (P=0.879), so data from both groups were included in the analyses. Patients tended to be men (69%) with a mean age of 55±15 (SD) years, and about half (44%) had an ischemic pathogenesis for their HF. The mean ejection fraction was 23%, and the population was evenly divided between functional class II and III symptoms. Forty-nine subjects (13%) experienced a total of 150 VT/VF episodes on 87 distinct days (3.1±4.8 episodes/subject; range 1–23). Six subjects experienced 3 to 5 VT/VF events on ≥1 days. One subject experienced 7 and 12 VT/VF events on 2 different days, and 1 subject experienced 23 VT/VF events on a single day.

Comparison of Patients With and Without VT/VF Events
The 49 subjects with at least 1 VT/VF event had a somewhat higher average baseline daily median ePAD (baseline ePAD was measured 8–14 days after implant) compared with the 329 subjects that were free of VT/VF events (24.4±9.7 mm Hg versus 21.9±7.0 mm Hg), but the difference was not statistically significant (P=0.080). Subjects who experienced at least 1 VT/VF event also had a shorter 6-minute hall walk distance, and worse physical health as measured by the SF-12 score at entry, possibly indicating more severe HF (Table 1). There was no difference in HF pathogenesis, left ventricular ejection fraction, or NYHA functional class between the 2 groups. Patients who experienced VT/VF events during the trial were more likely to have a history of PVC, but there was no difference in previous history of sustained VT, nonsustained VT, or VF/cardiopulmonary arrest in the 2 groups.

Average Follow-up Median ePAD as a Predictor of VT/VF Events
The average follow-up median ePAD was a predictor of VT/VF events. The univariate relationship between average follow-up median ePAD and the probability of having at least 1 VT/VF event is shown in Figure 2. The relationship is adequately described as a linear function. Based on a univariate model, the odds ratio for the probability of having at least 1 VT/VF episode during the 12-month randomized period associated with a 1-mm Hg increase in average follow-up median ePAD was 1.072 (95% confidence interval, 1.023–1.124; P=0.003). Using the propensity score–adjusted logistic regression model, the odds ratio associated with a 1-mm Hg increase was similar and remained a significant independent predictor of the likelihood of VT/VF (odds ratio, 1.053; 95% confidence interval, 1.002–1.106; P=0.043).

Table 1. Demographic Comparison of the Subjects With at Least 1 VT/VF Event and Subjects Free of VT/VF Events
<table>
<thead>
<tr>
<th>VT/VF Event (n=49)</th>
<th>VT/VF Free (n=329)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at implant</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Men</td>
<td>n=38, 78%</td>
<td>n=223, 68%</td>
</tr>
<tr>
<td>White</td>
<td>n=31, 63%</td>
<td>n=185, 56%</td>
</tr>
<tr>
<td>Ischemic pathogenesis</td>
<td>n=20, 41%</td>
<td>n=148, 45%</td>
</tr>
<tr>
<td>NYHA FC II</td>
<td>n=22, 45%</td>
<td>n=169, 51%</td>
</tr>
<tr>
<td>LVEF %</td>
<td>23.2 (7.7)</td>
<td>23.0 (7.4)</td>
</tr>
<tr>
<td>6-min hall walk, m</td>
<td>258 (116)</td>
<td>312 (126)</td>
</tr>
<tr>
<td>MN living with HF score†</td>
<td>58 (22)</td>
<td>50 (27)</td>
</tr>
<tr>
<td>SF-12 Physical Health Score</td>
<td>31 (9.2)</td>
<td>36 (10.2)</td>
</tr>
<tr>
<td>Baseline ePAD†</td>
<td>24.4 (9.7)</td>
<td>21.9 (7.0)</td>
</tr>
</tbody>
</table>

*P value from t test or Fisher exact test.
†Baseline ePAD calculated as the average daily median ePAD 8–14 days after IHM-ICD implant.

ePAD indicates estimated pulmonary artery diastolic pressures; HF, heart failure; LVEF, left ventricular ejection fraction; MN, Minnesota; and NYHA, New York Heart Association.
Of the 49 subjects who experienced at least 1 VT/VF event, 46 (12.2% of the 378 subjects) experienced a total of 140 adjudicated VT/VF events on 80 days when hemodynamic data were available. An additional 10 VT/VF events in 3 subjects occurred on days when hemodynamic data were unavailable and were therefore excluded from this analysis. For the population who had experienced at least 1 VT/VF episode, ePAD was in the hypervolemic range (ie, >1 SD above subject-specific mean) for 15.3% of the follow-up period (6.4 follow-up years; Table 2). Subjects were considered hypovolemic <2% of the follow-up period. The majority of time (83.3%) subject ePAD was considered to be in the euvolemic range.

There were 18 days with at least 1 VT/VF episode during a total of 6.4 patient-years of follow-up categorized as hypervolemic for an annualized rate of 2.80 episode days per year compared with an annualized rate of 1.69 episode days per euvolemic patient-year (P=0.040). Annualized VT/VF episodes during hypervolemic follow-up were also higher than during euvolemia, but this difference did not reach statistical significance (Table 2).

The annualized days with VT/VF episodes and the annualized number of VT/VF episodes also seemed to be higher during periods of hypovolemia than during periods of euvolemia, but the short duration of time subjects were hypovolemic preclude making a statistical inference. Only 5 episodes of VT/VF on 3 days occurred during periods of hypovolemia. If hypervolemia and hypovolemia are redefined as >1 SD above and >1 SD below subject-specific mean, respectively, the comparison of annualized episode days between hypervolemic and euvolemic periods remains significant (2.80 versus 1.69; P=0.047). With this broader definition of hypovolemia, the comparison of hypovolemic and euvolemic periods becomes less dramatic (2.04 annualized days/hypovolemic years versus 1.69 annualized days/euvolemic years; P=0.568).

The majority of ventricular events were adjudicated as monomorphic VT, as opposed to polymorphic VT/VF, in both hypervolemic and euvolemic periods (82% of events that occurred during hypervolemia and 67% of events that occurred during euvolemia were adjudicated as monomorphic VT; P=0.254).

When hypervolemia was defined by ePAD>25 mm Hg (mean ePAD for the whole population), the annualized rate of days with at least 1 episode of VT/VF per year of follow-up was not significantly different compared with periods when ePAD was <25 mm Hg (1.83 days with VT/VF per year).

### Table 2. Annualized VT/VF Rate by Pressure State (Subject Specific)

<table>
<thead>
<tr>
<th>Pressure State</th>
<th>Hypovolemia</th>
<th>Euvolemia</th>
<th>Hypervolemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject years in volume status</td>
<td>0.60</td>
<td>35.0</td>
<td>6.4</td>
</tr>
<tr>
<td>Days with at least 1 VT/VF episode</td>
<td>3</td>
<td>59</td>
<td>18</td>
</tr>
<tr>
<td>Annualized days with VT/VF</td>
<td>5.00</td>
<td>1.69</td>
<td>2.80</td>
</tr>
<tr>
<td>P value*</td>
<td>0.055†</td>
<td>0.040†</td>
<td></td>
</tr>
<tr>
<td>Number of VT/VF episodes</td>
<td>5</td>
<td>95</td>
<td>40</td>
</tr>
<tr>
<td>Annualized VT/VF rate</td>
<td>8.34</td>
<td>2.72</td>
<td>6.23</td>
</tr>
<tr>
<td>P value ‡</td>
<td>0.092‡</td>
<td>0.119‡</td>
<td></td>
</tr>
</tbody>
</table>

*Hypervolemia is defined as daily median estimated pulmonary artery diastolic pressures (ePAD) 1 SD higher than the subject’s average daily median ePAD for the whole follow-up period. Hypovolemia is defined as a daily median ePAD 2 SDs lower than the subject’s average daily median ePAD.

†P value from repeated measures Poisson model with number of days with VT/VF as response and volume status as independent variable.

‡P value compared with euvolemia.

§P value from repeated measures Poisson model with number of VT/VF episodes as response and volume status as independent variable.
year >25 mm Hg versus 1.96/y <25 mm Hg; P = 0.814). In contrast, if hypervolemia is defined as a pressure 3.5 mm Hg (average SD in daily ePAD) above the subject-specific median ePAD, then an association between pressure state and occurrence of VT/VF reappears (3.4 days with VT/VF per hypervolemic year versus 1.7 euvolemic year, P = 0.016; and 8.1 VT/VF episodes/hypervolemic year versus 2.7 VT/VF episodes/euvolemic year, P = 0.049). These data suggest that, among patients that had at least 1 VT/VF episode, the influence of changing pressure on risk of VT/VF is relevant but only when considered relative to each subjects’ baseline pressure.

Subjects with VT/VF events during hypervolemic periods were demographically very similar to subjects that experienced their VT/VF events during periods of euvolemia, although those experiencing VT/VF during hypervolemia were younger (46 versus 59; P = 0.007) and were less likely to have a history of atrial fibrillation (8% versus 44%; P = 0.035). Subjects with VT/VF during hypervolemia were more frequently in the active treatment group, but this difference was not significant (75% versus 44%; P = 0.096). Hypervolemia remained an independent predictor of VT/VF risk (P = 0.049) in this population after adjusting for these factors and randomized treatment group in the repeated measures Poisson model.

**Discussion**

This study was designed to ascertain whether there is a correlation between intracardiac pressures and susceptibility to ventricular arrhythmia development over an extended period of observation in an ambulatory, outpatient population with systolic HF. There were 3 principal findings. First, for individual patients, there is a statistically significant relationship between daily ePAD and the risk of a VT/VF event when the definition of increased pressure or volume status is subject specific. On days when the ePAD was higher than the subject mean, the risk of a VT/VF event was approximately twice that observed when pressures <25 mm Hg to days when ePAD was <25 mm Hg. This seems to be different from the relationship of intracardiac pressure and HF exacerbation.

Second, pressure thresholds unrelated to the subject’s specific state were not predictive of increased risk. There was no statistically significant difference in VT/VF incidence when comparing days with pressures >25 mm Hg to days when ePAD was <25 mm Hg. This seems to be different from the relationship of intracardiac pressure and HF exacerbation.

Third, for the whole population, the average ePAD during follow-up correlated with the risk of VT/VF events, and this correlation also parallels other indicators of ventricular dysfunction. Our analysis suggests a progressive risk of VT/VF as the ePAD increases with no apparent threshold below which the risk of VT/VF is zero.

**Comparison of Annualized Days With VT/VF Rate and Annualized VT/VF Rates**

Although there was a significant difference between days with VT/VF events based on pressure state, when annualized VT/VF rates were compared, the comparison failed to reach statistical significance. A potential explanation for this observation is suggested by Figure 1. A VT/VF event has the potential to transiently elevate ePAD, although pressures quickly tend to return to values preceding the arrhythmic event. An episode of VT/VF occurring during a period of euvolemia could then be associated with a brief period of elevated pressure that transiently increases the risk of arrhythmic events. This scenario could artificially increase the number of VT/VF events associated with presumed euvolemic if subsequent episodes result from these secondary transient pressure changes. Indeed our data may have been influenced disproportionally by subjects with electrical storm (6 of 9 days on which storm occurred were categorized either as euvolemic or hypovolemic, including 1 subject with 23 VT/VF episodes on a single euvolemic day).

**Mechanisms Linking Elevated Ventricular Pressures and Ventricular Arrhythmias**

There are several potential mechanisms by which an elevated ventricular pressure could influence the development of ventricular arrhythmias. Elevated ventricular pressure is a neurohormonal activator, increases sympathetic tone, and is associated with aberrant intracellular calcium cycling. Acute diastolic stretch shortens action potential duration and refractoriness, presumably because of activation of stretch-activated channels. Similar phenomena have been described in man. The observation, in the current study, that ventricular events are correlated with patient-specific changes in intracardiac pressure, and not absolute pressure, is consistent with observations in the above studies that show that acute chamber dilatation shortens myocardial refractoriness, whereas chronic dilatation does not.

Recent studies have analyzed the relationship of intrathoracic impedance, as a surrogate for intracardiac pressures, and spontaneous ventricular arrhythmias. Moore et al found that the sum of the daily differences between the average daily and reference impedences (7 days, 2 days, and 1 day before VT/VF) was negative before 66% of VT/VF episodes in 121 patients, only slightly >50% expected if the relationship was random. Although, statistically significant, the difference was small, the study retrospective, and the positive predictive value was low. Ip et al found that VT/VF episodes were more common when the OptiVol fluid index (representing the accumulation of consecutive day-to-day differences between the daily and reference intrathoracic impedance values) was >15, 30, and 45 ohm-days. Again, the predictive value was poor. The OptiVol fluid index does not reflect any specific value or level of HF but rather a change from baseline, and both of the measures these 2 studies used reflect relative and subject-specific changes.
Our study more directly demonstrates a relationship between subject-specific hemodynamic status and VT/VF occurrence. The critical factor seems to be an elevation from median values for a given individual. However, the correspondence between absolute ePAD value and VT/VF events is not tightly linked. Nearly 70% of observed VT/VF episodes occurred when subjects were considered euvoletic. It remains unclear whether elevated pressure is a determinant of ventricular arrhythmic events only in a susceptible subpopulation or whether as yet unidentified influences interact with intracardiac pressures to influence VT/VF events.

Limitations

Although the current study offers a unique approach to assessing the impact of intracardiac pressures on ventricular tachyarhythmia susceptibility in ambulatory patients with HF, it is nonetheless subject to a number of important limitations. First, although a relatively large population was assessed, the number of VT/VF episodes (event rate) was small. Although the study and data collection were prospectively planned, the analysis was retrospective and the population size and number of VT/VF events were smaller than originally expected. Second, the analysis used daily median ePAD measurements. Intracardiac pressures are dynamic, influenced by activity, posture, medications, and dysrhythmias. Variation of pressure during the day and over shorter periods of time were not available for this analysis. Third, as mentioned, it is possible that a stronger pressure-arrhythmia relationship exists in an, as yet undefined, unique patient population but is diluted out by a population relatively insensitive to elevated intracardiac pressure. Although in the present study, we could discern no notable demographic difference between subjects whose VT/VF events occurred during periods of hypervolemia from those whose VT/VF events occurred during euvoletic periods. Fourth, ePAD may not be the intracardiac pressure best correlated with susceptibility for ventricular arrhythmias. Analysis of this relationship with other measures of intracardiac pressure may be possible in the future. Finally, this analysis could not account for other potentially important data, such as electrolyte status or changes in therapy.

Conclusions

We have demonstrated a significant correlation between days with VT/VF events and preceding subject-specific changes in intracardiac pressures. The risk of a VT/VF occurrence is twice as likely when the daily median estimated PA pressure exceeds the subject mean by 1 SD. This supports the supposition that elevations in intracardiac pressures can influence the development of ventricular arrhythmias in a population with a history of congestive HF. Whether tighter control of intracardiac pressures based on an individual patient’s experience will diminish susceptibility to ventricular tachyarhythmias remains to be assessed.

Sources of Funding

Medtronic Inc supported the REDUCEhf trial (Clinical Trials.gov Identifier: NCT00354159) and the collection of data.

Disclosures

Drs Reiter, Benditt, Adamson, and Gold have served as consultants to Medtronic, Inc and St. Jude Medical. Dr Adamson also serves as consultant to CardioMEMS, Inc and RespiCardia, and has received speaking honoraria from Boston Scientific. Dr Gold has received research support from Medtronic, Inc and St. Jude Medical. Dr Benditt has ownership interest in Medtronic, Inc and St. Jude Medical. Authors Stromberg and Whitman are employees of Medtronic, Inc.

References

Prediction of ventricular arrhythmias (VAs) is a significant, continuing clinical challenge. The relationship between intracardiac pressure and VAs remains controversial. It is often suggested that elevated intracardiac pressure can precipitate VAs (and is a cause of electrical storm), but there is limited direct evidence supporting a connection. Implanted cardioverter-defibrillator devices capable of hemodynamic measurement provide the opportunity to directly examine the association between intracardiac pressure and the occurrence of VAs in humans. In a population of subjects with heart failure, in this study, it was observed that the risk of a VA was almost 2-fold greater on days when the PA diastolic pressure was elevated (ie, at least 1 SD greater than the subject-specific mean). Elevated daily intracardiac pressures were associated with higher VT/VF risk only when the definition of increased pressure was subject specific. The odds ratio associated with a 1-mm Hg increase in PA diastolic pressure over the whole follow-up period was also a significant independent predictor of the likelihood of VT/VF during follow-up (odds ratio, 1.053; 95% confidence interval, 1.002–1.106). Regardless of mechanism or whether elevated pressure is a determinant of VAs only in a susceptible subpopulation, confirmation of this association raises the possibility that stricter control of intracardiac pressure may be an important antiarrhythmic strategy.
Influence of Intracardiac Pressure on Spontaneous Ventricular Arrhythmias in Patients With Systolic Heart Failure: Insights From the REDUCEhf Trial
Michael J. Reiter, Kurt D. Stromberg, Teresa A. Whitman, Philip B. Adamson, David G. Benditt and Michael R. Gold

_Circ Arrhythm Electrophysiol_. 2013;6:272-278; originally published online March 20, 2013; doi: 10.1161/CIRCEP.113.000223

_Circulation: Arrhythmia and Electrophysiology_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circep.ahajournals.org/content/6/2/272

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Arrhythmia and Electrophysiology_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Arrhythmia and Electrophysiology_ is online at:
http://circep.ahajournals.org//subscriptions/